-
A trial fibrillation (AF) is a major source of morbidity in patients and cost to the health care community. In the presence of risk factors for thromboembolism, AF is associated with an increased risk of stroke, and this risk is reduced with warfarin.
-
Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.
-
In clinical practice, patients with atrial fibrillation (AF) duration < 48 hours often undergo cardioversion without systemic anticoagulation.
-
Medications for Risk Reduction of Breast Cancer in Women
-
Primary percutaneous coronary intervention (PCI) is the optimal treatment for patients suffering ST-elevation myocardial infarction (STEMI).
-
Multiple prospective, randomized trials have shown a mortality reduction in patients with reduced left ventricular ejection fraction who undergo prophylactic implantable cardioverter-defibrillator (ICD) therapy.
-
Evidence-based updates in primary care medicine By Louis Kuritzky, MD
-
Pacemaker or defibrillator leads have been shown to have attached thrombi in up to one-third of cases and asymptomatic pulmonary emboli have been documented in up to 20% of patients.
-
Dabigatran is a novel anticoagulant that has been shown to be at least as good as warfarin at preventing thromboembolism in atrial fibrillation (AF).
-
Computed tomography (CT) has evolved significantly in recent years, and is now able to accurately assess coronary arteries for the presence of atherosclerosis in carefully selected patients.
